Novo Nordisk Forecasts Narrowed Losses Amid Strong Demand for Wegovy and Ozempic
Novo Nordisk updated its full-year sales forecast on November 04, 2026, projecting that sales and operating profit will either decline or grow by up to 2% at constant exchange rates. GuruFocus reported that the revised outlook marks an improvement from the company’s earlier projection, which warned of a potential 6% decline. The adjustment stems from strong demand for the weight-loss drug Wegovy and the established diabetes treatment Ozempic.
The Danish pharmaceutical manufacturer posted net sales of DKK 79.19 billion in its third-quarter report, marking a 6% increase compared to the same period last year. Adjusted operating profit surged 34% to DKK 31.7 billion, beating analyst expectations. Wegovy generated DKK 5.39 billion during the quarter, surpassing prior market projections. Headquartered in Bagsvaerd, Denmark, the company supplies roughly half of the world’s insulin and markets GLP-1 receptor agonists such as semaglutide.
Evaluate Dividend Yields Against Historical Valuation Multiples
Novo Nordisk offers a dividend yield of 4.37% supported by a payout ratio of 10% and a three-year compound annual growth rate of 23.6%. The company’s GF Value stands at $101.39, while shares trade on the New York Stock Exchange at $40.19 under the ticker NVO, indicating an undervaluation of approximately 60.4% according to GuruFocus proprietary metrics. The trailing price-to-earnings ratio sits at 10.32x, remaining well below its five-year median of 35.39x.
GuruFocus tracks 13 institutional gurus holding shares in the drug manufacturer. Recent quarters show seven gurus trimmed their positions while five added shares, reflecting balanced sentiment among large investors. Insider buying and selling activity remained absent over the preceding 12 months.
Profitability and Financial Strength Ratings
The company holds a GF Score of 75 out of 100, driven by strong operational efficiency and balance sheet stability. Financial metrics reflect an operating margin of 45.37% and a net margin of 35.35%. Financial strength is shown by an Altman Z-Score of 3.79, pointing to low bankruptcy risk. Growth metrics score moderately with a three-year revenue growth rate of 21.3%, though recent expansion has slowed. Valuation metrics register lower due to the share price trading below historical valuation multiples.
Global Expansion Plans for 2027
Novo Nordisk plans to expand the availability of Wegovy to more than 20 international markets in 2027. The geographic rollout aims to capture expanding demand within the global obesity treatment sector as competition intensifies against rival drugmaker Eli Lilly. Market capitalization for Novo Nordisk stands at $179.49 billion within the healthcare sector and drug manufacturing industry.
BREAKING: $NVO Raises Full-Year Guidance After Stronger-Than-Expected Q3 Results Novo Nordisk has reported its Q3 2026 results, delivering stronger-than-expected performance driven by continued GLP-1 growth, particularly in obesity treatments. Q3 Financial Results • Revenue…
Assess Novo Nordisk Financial Score and Dividend Safety
What is Novo Nordisk’s GF Score?
The company holds a GF Score of 75 out of 100, reflecting strong marks in profitability and financial strength paired with moderate growth and valuation metrics.
Is the NVO dividend considered safe?
Yes, the dividend is supported by a 4.37% yield, a low payout ratio of 10%, and a three-year dividend growth rate of 23.6%, which indicates strong free cash flow generation.
How does the current valuation compare historically?
The trailing P/E ratio of 10.32x trades significantly below the five-year median P/E of 35.39x, placing the stock well under historical valuation levels.
Keep reading